Browse
Submit Data
Databases
API
Help

Dataset Information

12 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Randomized Phase II study of Bevacizumab with SOX versus Bevacizumab with XELOX as second-line therapy in metastatic colorectal cancer which has prior therapy of S-1 and CPT-11

ABSTRACT: Interventions: SOX+Bevacizumab Bevacizumab 7.5mg/kg/triweekly L-OHP 130 mg/m2/triweekly TS-1 80,100,120 mg/twice/day 1-14, following one week off XELOX+Bevacizumab Bevacizumab 7.5mg/kg/triweekly L-OHP 130 mg/m2/triweekly Capecitabine 2400-4200 mg/twice/day 1-14, following one week off Primary outcome(s): Progression-free survival (PFS) Study Design: Parallel Randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2622332 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A randomized phase III study of oxaliplatin based chemotherapy versus combination chemotherapy of TS-1,irinotecan and bevacizumab as first line therapy for unresectable or recurrent colorectal cancer

Project description:Interventions: arm A-1:mFOLFOX6+Bevacizumab Bevacizumab 5mg/kg/bi-week L-OHP 85mg/m2/bi-week l-LV 200mg/m2/bi-week 5-FU/bolus 400mg/m2/bi-week 5-FU/infusional 2,400mg/m2/bi-week arm A-2: CapeOX+Bevacizumab Bevacizumab 7.5mg/kg/tri-week L-OHP 130mg/m2/tri-week Capecitabine 1200-2100mg/twice/day(day 1-15) arm B-1:TS-1/CPT-11+Bevacizumab(SIRB) Bevacizumab 7.5mg/kg/tri-week CPT-11 150mg/m2/tri-week S-1 40-60mg/twice/day(day1-15)/tri-week arm B-2:TS-1/CPT-11+Bevacizumab(IRIS/BV) Bevacizumab 5mg/kg/(day1and15)/4-weeks CPT-11 100mg/m2/(day1and15)/4-weeks S-1 40-60mg/twice/day(day1-15)/4weeks Primary outcome(s): Progression free survival(PFS) Study Design: Parallel Randomized

| 2623247 | ecrin-mdr-crc

JCOG1018: Rp3 Study in Elderly Patients with MEtastatic CRC as 1st-line Tx

Project description:Interventions: Arm A: 5-FU/LV or CAP + BEV 1. 5-FU/l-LV (msDG) + BEV (1) BEV: 5 mg/kg, iv, day 1 (2) l-LV: 200 mg/m2, iv, day 1 (3) 5-FU: 2,400 mg/m2/46 hr, civ, day 1-3 2. CAP + BEV [ 50 mL/min <= Ccr ] (1) BEV: 7.5 mg/kg, iv, day 1 (2) CAP: 1,250 mg/m2, oral, twice a day, day 1-14 [ 30 mL/min <= Ccr<50 mL/min ] (1) BEV: 7.5 mg/kg, iv, day 1 (2) CAP: 1,000 mg/m2, oral, twice a day, day 1-14 Arm B: 5-FU/LV or CAP + L-OHP + BEV 1. mFOLFOX7 + BEV (1) BEV: 5 mg/kg, iv, day 1 (2) l-LV: 200 mg/m2 + L-OHP:85 mg/m2, iv, day 1 (3) 5-FU: 2,400 mg/m2/46 hr, civ, day 1-3 2. CAPOX + BEV [ 50 mL/min <= Ccr ] (1) BEV: 7.5 mg/kg, iv, day 1 (2) l-LV: 130 mg/m2, iv, day 1 (3) CAP: 1,000 mg/m2,oral, twice a day, day, day 1-14 [ 30 mL/min <= Ccr < 50 mL/min ] (1) BEV: 7.5 mg/kg, iv, day 1 (2) L-OHP: 130 mg/m2, iv, day 1 (3) CAP: 750 mg/m2, oral, twice a day, day 1-14 Primary outcome(s): Progression-free survival Study Design: randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose

| 2614012 | ecrin-mdr-crc

XELOX(+bevacizumab), efficacy, safety, QOL Study:FOLFOX(+bevacizumab) after starting therapy, for patients can’t continue continuous infusion therapy

Project description:Interventions: 1000mg/m2 of oral Xeloda twice daily on days 1 through 14 every 3 weeks. L-OHP 130mg/m2 is administered intravenous injection on day 1. (Bevacizumab 7.5mg/kg is administered intravenous injection on day 1.) Primary outcome(s): FOLFOX(+bevacizumab) from PFS Study Design: Single arm Non-randomized

| 2619416 | ecrin-mdr-crc

A randomized Phase II study comparing SOX+B-mab with SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with KRAS wild type.

Project description:Interventions: A group (SOX+B-mab) TS-1 administered for 14 days followed by 7 days rest according to body surface area. L-OHP is administered intravenously in 130 mg/m2 at day 1. B-mab is administered intravenously in 7.5 mg/kg by tri-weekly. B group (SOX+C-mab) TS-1 administered for 14 days followed by 7 days rest according to body surface area. L-OHP is administered intravenously in 130 mg/m2 at day 1. C-mab is administered intravenously in 400 mg/m2 on day 1, then 250 mg/m2 weekly thereafter. Or C-mab is administered intravenously in 500 mg/m2 by bi-weekly. Primary outcome(s): Response rate Study Design: Parallel Randomized

| 2622133 | ecrin-mdr-crc

Randomized pilot study comparing safety of irinotecan+S-1(IRIS)+bevacizumab and mFOLFIRI+bevacizumab for metastatic colorectal cancer (T-CORE0702)

Project description:Interventions: FOLFIRI + bevacizumab consisted of bevacizumab 5mg/kg as a 90-minute infusion, then, l-LV 200 mg/m2 as a 2-hour infusion, and irinotecan 150 mg/m2 given as a 90-minute infusion, followed by bolus FU 400 mg/m2 and a 46-hour infusion FU 2,400 mg/m2, repeated every 2 weeks. IRIS + bevacizumab consisted of bevacizumab 7.5mg/kg as a 90-minute infusion, then, irinotecan 150 mg/m2 given as a 90-minute infusion, followed by oral S-1 (40 mg/m2) twice daily 14 days (day 3 to 16) followed by 5 days rest, repeated every 3 weeks. Primary outcome(s): safety Study Design: Parallel Randomized

| 2616274 | ecrin-mdr-crc

Gunma study - Oxaliplatin-based chemotherapy and Avastin following Irinotecan-based chemotherapy with Erbitux in metastatic colorectal cancer

Project description:Interventions: first line chemotherpy FOLFIRI+Cetuximab (Cetuximab 500mg/m2/bi-week CPT-11 150mg/m2/bi-week l-LV 200mg/m2/bi-week 5-FU/bolus 400mg/m2/bi-week 5-FU/infusional 2,400mg/m2/bi-week (day 1-3)) FOLFIRI+Cetuximab second line chemotherapy (1) mFOLFOX6+Bevacizumab (Bevacizumab 5mg/kg/bi-week L-OHP 85mg/m2/bi-week l-LV 200mg/m2/bi-week 5-FU/bolus 400mg/m2/bi-week 5-FU/infusional 2,400mg/m2/bi-week (day 1-3)) second line chemotherapy (2) XELOX+Bevacizumab (Bevacizumab 7.5mg/kg/tri-week L-OHP 130mg/m2/tri-week Capecitabine 2000mg/m2/day/2 (day 1-15)) Primary outcome(s): Total Progression free survival (PFS1+PFS2): PFS during first-line (PFS1) and PFS during second-line (PFS2) Study Design: Single arm Non-randomized

| 2622536 | ecrin-mdr-crc

Research on biomarkers in cetuximab containing combination therapies for patients with KRAS wild-type metastatic colorectal cancer

Project description:Interventions: cetuximab loading dose 400mg/m2, 250mg/m2/week L-OHP 85mg/m2/biweekly levofololinate 200mg/m2/biweekly 5-FU bolus 400 mg/m2/biweekly 5-FU continuous 2,400 mgm2/biweekly / cetuximab loding dose 400 mg/m2, 250 mg/m2/week L-OHP 75-130 mg/m2/tri-weekly S-1 80-120 mg/day, day1-14 Primary outcome(s): Correlation between the reported biomarkers (EGFR expression, ligand expression to EGFR, BRAF, PI3K, and PTEN expression) or new ones (DNA microarray, analysis of microRNA expression, and DNA SNP analysis) and the response to cetuximab containing combination therapies Study Design: Parallel Randomized

| 2626017 | ecrin-mdr-crc

A randomized controlled trial comparing resection of primary tumor plus chemotherapy with chemotherapy alone in incurable Stage IV colorectal cancer(JCOG1007, iPACS)

Project description:Interventions: A: Chemotherapy alone (mFOLFOX6 or CapeOX plus bevacizumab; mFOLFOX6: bevacizumab 5 mg/kg IV on day 1, l-leucovorin 200 mg/m2 and oxaliplatin 85 mg/m2 as a 2-hour IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 followed by 2,400 mg/m2 IV over 46 hours, repeated every 2 weeks; CapeOX: bevacizumab 7.5 mg/kg IV on day 1, l-leucovorin 130 mg/m2 on day 1 and Capecitabine 1000 mg/m2 per day orally from day 1 to day 14, repeated every 2 weeks) B: Primary resection followed by chemotherapy (mFOLFOX6 or CapeOX plus bevacizumab; mFOLFOX6: bevacizumab 5 mg/kg IV on day 1, l-leucovorin 200 mg/m2 and oxaliplatin 85 mg/m2 as a 2-hour IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 followed by 2,400 mg/m2 IV over 46 hours, repeated every 2 weeks; CapeOX: bevacizumab 7.5 mg/kg IV on day 1, l-leucovorin 130 mg/m2 on day 1 and Capecitabine 1000 mg/m2 per day orally from day 1 to day 14, repeated every 2 weeks) Primary outcome(s): Overall survival Study Design: Parallel Randomized

| 2623557 | ecrin-mdr-crc

Phase II study of S-1+CPT-11+Bevacizumab as second-line therapy in metastatic colorectal cancer which has prior therapy of S-1+L-OHP+Bevacizumab

Project description:Interventions: Bevacizumab 7.5mg/kg/tri-week CPT-11 150mg/m2/tri-week S-1 40-60mg/twice/day(day1-15)/tri-week Primary outcome(s): Progression-free survival Study Design: Single arm Non-randomized

| 2630432 | ecrin-mdr-crc

Multicenter Phese II Study of SOX plus Bevacizumab Therapy with Oxaliplatin Stop-and-Go Strategy and Oral S-1 plus Bevacizumab Maintenance Therapy in Advanced Colorectal CancerC

Project description:Interventions: (1)Initial therapy : SOX+bevacizumab therapy Bev : 7.5 mg/kg (90 min) L-OHP : 130 mg/m2 (120 min) S-1 : 80 - 120 mg/day (Day1-15) (2)Maintenance therapy : S-1+bevacizumab therapy Bev : 7.5 mg/kg (90 min) S-1 : 80 - 120 mg/day (Day1-15) (3)Reintroduced therapy : SOX+bevacizumab therapy Primary outcome(s): DDC ; Duration of disease control) Study Design: Single arm Non-randomized

| 2627046 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data